Small Cell Lung Carcinoma
📧 Sign up to get email alerts when something new happens for Small Cell Lung Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-08-25EMA Application withdrawn: Zinmyleo (trilaciclib dihydrochloride) — Pharmacosmos A/S
The EMA has withdrawn the application for Zinmyleo (trilaciclib dihydrochloride) by Pharmacosmos A/S for small cell lung carcinoma.
-
EMA approval · 2026-07-21EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Roche's Tecentriq (atezolizumab) has been authorised by the EMA for multiple indications including transitional cell carcinoma, non-small ce…
-
EMA approval · 2026-07-13EMA Authorised: Hetronifly (serplulimab) — Accord Healthcare S.L.U.
European Medicines Agency authorises Hetronifly (serplulimab) for multiple indications including small cell lung cancer, non-small cell lung…
-
EMA approval · 2026-04-28EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Authorised status for Tecentriq (atezolizumab) by Roche Registration GmbH across multiple cancer indications in the European market.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update indicates YL201 is being studied in combination with other anti-cancer therapies for patients with advanced solid tumo…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: A Safety Study of 212Pb-Pentixather Radioligand Therapy [EARLY_Phase 1]
An early-phase safety study of the radioligand therapy 212Pb-Pentixather is not yet recruiting, evaluating its use for lung carcinoid tumors…
-
CLINICAL_TRIALS research · 2025-06-13Clinical Trial Update: DOTATOC PET/CT for Imaging NET Patients
ClinicalTrials.gov entry describes a DOTATOC PET/CT imaging study for neuroendocrine tumors, sponsored by the British Columbia Cancer Agency…
-
CLINICAL_TRIALS trial_result · 2025-01-14Clinical Trial Update: Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors [Phase 1]
A Phase 1 trial update reports completion of a study evaluating an immunotherapy in combination with chemoradiation for advanced solid tumor…
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer [Phase 3]
Phase 3 trial of RRx-001 with platinum doublet in small cell lung cancer was terminated.
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer [Phase 2]
Phase 2 trial evaluating biomarkers for nivolumab and ipilimumab and their combination in lung cancer.
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: PEN-866 in Patients With Advanced Solid Malignancies [Phase 1, Phase 2]
Clinical trial update for PEN-866 across multiple phases investigating advanced solid malignancies, including endometrial adenocarcinoma and…
-
CLINICAL_TRIALS trial_result · 2021-07-02Clinical Trial Update: A Study of AK-01 (LY3295668) in Solid Tumors [Phase 1, Phase 2]
A two-phase clinical trial evaluating AK-01 (LY3295668) in solid tumors has completed phases 1 and 2 with posted results.
-
CLINICAL_TRIALS trial_result · 2020-07-01Clinical Trial Update: A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） [Phase 2]
Phase 2 trial evaluating sequential camrelizumab with chemotherapy (irinotecan + platinum) followed by apatinib in untreated advanced small …
-
EMA withdrawal · 2019-03-07EMA Withdrawn: Topotecan Actavis (topotecan) — Actavis Group PTC ehf
EMA withdrawn topotecan (Topotecan Actavis) indicated for uterine cervical neoplasms and small cell lung carcinoma; product withdrawn by MAH…
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma [Phase 1]
Phase 1 trial update for GSK2879552 in relapsed/refractory small cell lung carcinoma has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2019-01-10Clinical Trial Update: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors [Phase 1]
Phase 1 trial of talazoparib in advanced or recurrent solid tumors shows safety data and preliminary activity; results posted.
-
EMA withdrawal · 2018-07-13EMA Withdrawn: Topotecan Teva (topotecan) — Teva B.V.
Topotecan Teva has been withdrawn from the market by Teva B.V., affecting indications in ovarian neoplasms, uterine cervical neoplasms, and …
-
EMA withdrawal · 2014-11-14EMA Withdrawn: Topotecan Eagle (topotecan hydrochloride) — Eagle Laboratories Ltd.
EMA has withdrawn Topotecan Eagle (topotecan hydrochloride) from the market.
-
CLINICAL_TRIALS trial_result · 2013-04-17Clinical Trial Update: A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide [Phase 1, Phase 2]
Phase I/II study evaluating the maximum tolerated dose and safety of CC-4047 (pomalidomide) with cisplatin and etoposide in small cell carci…